Cardio Diagnostics secures U.S. patent for cardiovascular disease detection technology

Cardio Diagnostics Holdings, Inc.

U.S. Patent No. 11,414,704 issued by USPTO to University of Iowa Research Foundation (UIRF), exclusively licensed to Cardio Diagnostics.
Patent covers compositions and methods for detecting predisposition to cardiovascular disease; co-invented by Cardio founders/CEO Meesha Dogan and CMO Robert Philibert.
The patent technology is used in Cardio's flagship product Epi+Gen CHD, a three-year symptomatic CHD risk assessment test introduced in 2021.
Cardio Diagnostics is merging with Mana Capital Acquisition Corp. (Nasdaq: MAAQU) in a previously announced business combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.